申请人:Institute of Medicinal Molecular Design, Inc.
公开号:EP1145718A1
公开(公告)日:2001-10-17
A medicament comprising as an active ingredient a compound or a physiologically acceptable salt thereof represented by general formula (I):
wherein R1 represents a dicarba-closo-dodecaboran-yl which may be substituted with a lower alkyl group, a lower alkenyl group, carboxyl group or the like; R2 represents carboxyl group, a lower alkoxycarbonyl group, or hydroxyl group; and X represents a single bond or a linking group such as -CO-Y1- wherein Y1 represents oxygen or -N(R3)-wherein R3 represents hydrogen or a lower alkyl.
一种药物,其活性成分为由通式(I)表示的化合物或其生理上可接受的盐,其中R1代表可用较低的烷基基团、较低的烯基基团、羧基等取代的二碳杂十二硼基;R2代表羧基、较低的烷氧羰基,或羟基;X代表单键或类似-CO-Y1-的连接基团,其中Y1代表氧或-N(R3)-,其中R3代表氢或较低的烷基。